

Special Issue

Sepsis Management and Critical Care

Message from the Guest Editor

Personalization in intensive care is increasingly invoked. However, there are not many studies or reviews focused on this aspect and with this vision. In this issue of the *Journal of Personalized Medicine* we will try to address some of the most controversial or interesting aspects of the treatment of sepsis and in critical care from this point of view. We do not intend to answer everything, nor cover all the topics, but the topics included in this issue will have a vision aimed at individualization or at least phenotyping of septic patient management, and critical care. High-risk patients with sepsis and multi-organ failure, in intensive care, and the diagnosis, monitoring and therapies used in critical care are a challenge, because there is no size fits all. Our interest is proportional to the reading of this special issue some light in some of the aspects related to those challenges.

Guest Editor

Dr. Fernando Ramasco-Rueda

Department of Anesthesia and Surgical Intensive Care, Hospital Universitario de La Princesa, Madrid, Spain

Deadline for manuscript submissions

closed (31 December 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/165178

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://mdpi.com/journal/)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).